大蒜素辅助治疗支气管扩张症急性加重的临床研究

Allicin as an add-on treatment in acute exacerbation of bronchiectasis ： a clinical study

目的探讨大蒜素辅助治疗支气管扩张症急性加重患者的临床疗效。方法收集2015年10月至2017年10月本院收治的支气管扩张症急性加重患者120例，按随机数字表分成对照组（n=60）及观察组（n=60）。对照组予常规治疗，观察组在常规治疗基础上口服大蒜素辅助治疗。治疗前及治疗1周后记录两组患者的感染相关指标，包括血清C反应蛋白（CRP）、降钙素原（PCT）、中性粒细胞比例（N％）。治疗l周后评估临床疗效，记录治疗相关不良反应的发生情况。结果两组患者治疗后血清CRP、PCT、N％较治疗前均显著下降（均P〈0．05）。与对照组比较，治疗后观察组患者血清CRP、PCT、N％均显著降低（均P〈0．05）。观察组与对照组患者治疗有效率分别为66．7％（40／60）、58．3％（35／60），组间比较差异无统计学意义（χ^2=0．889，P=0．346）。观察组患者中出现胃肠道反应3例，均停药后好转；对照组患者中未出现明显不良反应。结论大蒜素辅助治疗可使支气管扩张症急性加重患者获益，且其不良反应较小。

Objective To investigate the clinical efficacy of allicin in the treatment of acute exacerbation of bronchiectasis. Methods Included in this study were 120 patients with acute exacerbation of bronchiectasis admitted to our hospital between October 2015 and October 2017. Using a random number table, the patients were assigned to a control group （n=60） or a study group （n=60）. The control group received routine treatment, while the study group received oral allicin in addition to the routine treatment. Before and at 1 week after treatment, inflammatory biomarkers in the two groups were examined, including serum C-reactive protein （CRP） , procalcitonin （PCT） , and neutrophil percentage （N%）. At 1 week after treatment, the clinical efficacy was evaluated and the occurrence of treatment-related adverse reactions was recorded. Results After treatment, serum levels of CRP and PCT, and N% were significantly lowered in the both groups from baseline （all P〈0.05）. Compared with the control group, the post-treatment serum levels of CRP and PCT, and N% in the study group were significantly lower （all P〈0.05）. The effective rates of treatment in the study group vs the control group were 66.7% （40/60） vs 58.3% （35/60）, with no significant difference between two groups （X^2=0.889, P=0.346）. Gastrointestinal reactions occurred in 3 patients in the study group, and they all resolved after discontinuation of allicin. There were no obvious adverse reactions in the control group. Conclusion Allicin as an add-on treatment may be beneficial for patients with acute exacerbation of bronchiectasis with modest adverse reactions.